@vector ,

I don't see pancreatic cancer listed on the patient choice page, but Natera is still publishing papers related to it:
https://www.natera.com/resource-library/signatera/early-relapse-detection-and-monitoring-disease-status-in-patients-with-early-stage-pancreatic-adenocarcinoma-using-circulating-tumor-dna/
and
https://www.natera.com/company/news/nature-medicine-publishes-two-studies-highlighting-signateras-clinical-utility-in-patients-with-gastrointestinal-malignancies/
which includes the text:
"The test is available for clinical and research use and is covered by Medicare for patients with colorectal cancer, breast cancer (stage IIb and higher) and muscle invasive bladder cancer, as well as for immunotherapy monitoring of any solid tumor."

^Solid tumor^ being the keyword for pancreatic cancer.

I'm aware of two major pancreas CoE hospitals that regularly use the test for pancreatic cancer.